Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Blood (2021) 137 (20): 2785–2799.

https://doi.org/10.1182/blood.2020005244

Published: 2021

Includes: Supplemental data

Journal Articles

MyD88 L265P Mutation-Specific TCR Gene Therapy for Treatment of B-Cell Lymphoma and Leukemia

Özcan Çinar, BSc,MSc, Peter Michael Kloetzel, Caroline Anna Peuker, Ulrich Keller, Antonio Pezzutto, Antonia Busse

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-142880

Published: 2020

Journal Articles

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Ulrich Keilholz, Anne Letsch, Antonia Busse, Anne Marie Asemissen, Sandra Bauer, Igor Wolfgang Blau, Wolf-Karsten Hofmann, Lutz Uharek, Eckhard Thiel, Carmen Scheibenbogen

Blood (2009) 113 (26): 6541–6548.

https://doi.org/10.1182/blood-2009-02-202598

Published: 2009

Journal Articles

Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?.

Ulrich Keilholz, MD, Anne Letsch, MD, Antonia Busse, MD, Annemarie Asemissen, MD, Igor W. Blau, MD, Wolf K. Hofmann, MD, Lutz Uharek, MD, Eckhard Thiel, MD, Carmen Scheibenbogen, MD

Blood (2007) 110 (11): 902.

https://doi.org/10.1182/blood.V110.11.902.902

Published: 2007

Journal Articles

Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial.

Ulrich Keilholz, MD, Anne Letsch, Antonia Busse, Anne M. Asemissen, Alexander Schmittel, Wolf K. Hofmann, Lutz Uharek, Igor W. Blau, Eckhard Thiel, Carmen Scheibenbogen

Blood (2006) 108 (11): 567.

https://doi.org/10.1182/blood.V108.11.567.567

Published: 2006

Journal Articles

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2

Robert Godal, Ulrich Keilholz, Lutz Uharek, Anne Letsch, Anne Marie Asemissen, Antonia Busse, Il-Kang Na, Eckhard Thiel, Carmen Scheibenbogen

Blood (2006) 107 (8): 3205–3211.

https://doi.org/10.1182/blood-2005-07-2880

Published: 2006

NARROW

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

MyD88 L265P Mutation-Specific TCR Gene Therapy for Treatment of B-Cell Lymphoma and Leukemia

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?.

Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial.

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2

Email alerts

ASH Publications

American Society of Hematology

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

MyD88 L265P Mutation-Specific TCR Gene Therapy for Treatment of B-Cell Lymphoma and Leukemia

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?.

Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial.

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only